P3851 - Assessing Patient Preferences for Blood-Based Colorectal Cancer (CRC) Screening Tests: Insights from a Conjoint Analysis with Over 1,000 People in the US

Allistair Clark, MA¹, Marie Lauzon, MS¹, Noelle M. Griffin, PhD², Lance Baldo, MD², Brennan Spiegel, MD, MSHS¹, Christopher Almario, MD^1
1Cedars-Sinai Medical Center, Los Angeles, CA; ²Freenome, South San Francisco, CA

Introduction: Over one-third of people in the US are not up-to-date with CRC screening, and emerging blood-based tests offer a promising addition to existing options. Here, we used conjoint analysis to quantify the proportion of people who would prefer a hypothetical blood test over traditional approaches (eg, fecal immunochemical test [FIT], multitarget stool DNA test [mt-sDNA], colonoscopy).

Methods: We conducted a conjoint analysis survey in a nationally representative sample of average risk people aged 40-75 years who were not up-to-date with CRC screening. The conjoint determined the relative importance of test attributes in their decision making (eg, modality [blood test, stool test, colonoscopy, etc.], test frequency, accuracy at detecting CRC and advanced adenomas [AA], bowel prep, etc.). We also used latent class analysis to identify groups with similar decision-making profiles. Finally, we performed simulations with the conjoint data to estimate the proportion of people who would prefer a hypothetical blood test Q3 years over existing test options: FIT Q1 year, mt-sDNA Q3 years, colonoscopy Q10 years.

Results: Overall, 1,009 participants across the US completed the online survey. Using latent class analysis, we identified 2 distinct groups: (i) prioritized how the test is done—39.4%; (ii) prioritized accuracy of the test at detecting CRC/AAs—60.6%. The Table shows results from the multivariable logistic regression; 50-75 year-olds and women were more likely to prioritize how the test is done in their decision making. Conversely, non-Hispanic Blacks and those who plan to get screened were more likely to prioritize accuracy of the test. The Figure shows participants’ preferred tests stratified by latent class assignment. Among participants who prioritized the way the test is done in their decision making, most preferred a blood test Q3 years (65.1%), followed by mt-sDNA Q3 years (18.8%), FIT Q1 year (15.1%), and colonoscopy Q10 years (1.0%). For the group that prioritized test accuracy, most people also preferred the blood test (53.0%), followed by colonoscopy (20.6%), mt-sDNA (18.2%), and FIT (8.2%).

Discussion: Our findings indicate that most people, regardless of whether they prioritized test modality or accuracy in their decision making, prefer a hypothetical blood-based CRC screening test over traditional methods. This suggests that availability of FDA-approved blood tests could significantly improve CRC screening uptake, particularly among people who are unscreened or not up-to-date.



Disclosures:


Allistair Clark, MA¹, Marie Lauzon, MS¹, Noelle M. Griffin, PhD², Lance Baldo, MD², Brennan Spiegel, MD, MSHS¹, Christopher Almario, MD¹. P3851 - Assessing Patient Preferences for Blood-Based Colorectal Cancer (CRC) Screening Tests: Insights from a Conjoint Analysis with Over 1,000 People in the US, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.